Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H2 2018

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H2 2018

Summary

According to the recently published report Tyrosine Protein Kinase Fyn - Pipeline Review, H2 2018; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 7 molecules.

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.

The report Tyrosine Protein Kinase Fyn - Pipeline Review, H2 2018 outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 1, 2, 2 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Cardiovascular, Hematological Disorders, Musculoskeletal Disorders and Womens Health which include indications Alzheimers Disease, Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Peripheral T-Cell Lymphomas (PTCL), Systemic Mastocytosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Bile Duct Cancer (Cholangiocarcinoma), Cancer Pain, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Epithelial Ovarian Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Lymphangioleiomyomatosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Obesity, Oligodendroglioma, Ovarian Cancer, Parkinsons Disease, Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Psychosis, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AB Science SA
AstraZeneca Plc
Bristol-Myers Squibb Co
Nexus BioPharma Inc
ValiRx Plc
Zen-Bio Inc
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Drug Profiles
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FYN Kinase for Obesity and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Oct 22, 2018: AB Science announces that the masitinib phase 3 study in Alzheimers disease has completed patient recruitment
Oct 17, 2018: Valirx Val201 enters the concluding stages of its phase l/ll clinical trial
Oct 08, 2018: AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS
Sep 06, 2018: VALIRX: Update on clinical development of VAL201 compound
Aug 30, 2018: U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Jul 23, 2018: AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
Jul 17, 2018: US patent grant for therapeutic compound, VAL301
Jul 05, 2018: BMS Sprycel secures European nod to treat Ph+ CML
May 28, 2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
May 15, 2018: EMA Recommends a New Formulation and Extension of Indications for Dasatinib
Apr 25, 2018: ValiRx Announces EU Patent Grant For Therapeutic Compound, VAL201Completes Wide Global Coverage For Therapeutic Use
Apr 19, 2018: AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
Mar 22, 2018: EPFL: Attacking lymphoma at the source
Mar 20, 2018: Us Patent Grant For Therapeutic Compound, VAL201
Jan 11, 2018: US Patent Notice Of Allowance For Therapeutic Compound, VAL201
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AB Science SA, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Nexus BioPharma Inc, H2 2018
Pipeline by ValiRx Plc, H2 2018
Pipeline by Zen-Bio Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List Of Figures


Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Southeast Asia L-Alanyl-L-Tyrosine (CAS 3061-88-9) Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Southeast Asia L-Alanyl-L-Tyrosine market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by the

USD 3000 View Report

Southeast Asia Metyrosine (CAS 672-87-7) Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Southeast Asia Metyrosine market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by the

USD 3000 View Report

Rho Kinase (Rho-Associated Coiled-Coil Forming Protein Kinase or ROCK) Inhibitor -Pipeline Insight, 2019

Rho Kinase (Rho-Associated Coiled-Coil Forming Protein Kinase or ROCK) Inhibitor - Pipeline Insight, 2019 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects

USD 1250 View Report

Protein Kinase C (PKC) Inhibitor -Pipeline Insight, 2019

Protein Kinase C (PKC) Inhibitor - Pipeline Insight, 2019 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Protein Kinase C (PKC)

USD 1250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available